Pancreatic cancer, prostate cancer, Parkinson's syndrome, Alzheimers disease
Conditions
Interventions
Patients initially suspected of or diagnosed with pancreatic cancer:None
Patients suspected of or diagnosed with prostate cancer for the first time:None
Patient suspected of PD at initial consultation:None
Patient suspected of AD at initial consultation:None
Healthy control group:None
Sponsors
Department of Nuclear Medicine, The First Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. For patients with initially suspected or confirmed pancreatic cancer, whole-body PET/CT imaging with [68Ga]Ga-FAPI-04 plus [18F]FDG is required; for those with initially suspected or confirmed prostate cancer, whole-body PET/CT imaging with [68Ga]Ga-PSMA-11 plus [18F]FDG is indicated; or dual-molecular probe whole-body PET/CT imaging is necessary for suspected postoperative recurrence or metastasis to other sites. 2. Patients with Parkinson's disease (PD): meeting the International Parkinson and Movement Disorder Society diagnostic criteria for PD. Including: 1) bradykinesia; 2) at least one of muscular rigidity, resting tremor, or postural instability; 3) at least one of unilateral onset, persistent resting tremor, progressive course, predominantly asymmetrical involvement after onset, and a significant response to levodopa (70%-100%). 3. Patients with Alzheimer's disease (AD): according to the diagnostic criteria set by the American Alzheimer's Association in 2024. The diagnosis is supported by clinical cognitive assessment; cognitive impairment is mainly characterized by memory decline, without severe neuropsychiatric symptoms (such as aggression or severe agitation), and can cooperate with examinations with the assistance of a caregiver; without other central nervous system diseases (such as cerebrovascular disease, Lewy body dementia, cerebral amyloid angiopathy, etc.) to avoid confounding imaging result analysis. 4. Enrollment criteria for healthy control group include: 1) overall good health; 2) age and gender matched with the patient groups.
Exclusion criteria
Exclusion criteria: 1. Common exclusion criteria for PET use (e.g., implantable medical devices such as aneurysm clips, tattoos, claustrophobia, high fever, etc.); 2. Alcohol or drug dependence; 3. Major psychiatric disorders: including anxiety disorders, depression, affective disorders, schizophrenia, or drug-induced psychosis; 4. Neurological diseases: including cerebral infarction, brain tumors, cranial trauma, etc.; 5. Severe internal medical conditions, currently using respiratory drugs, cardiovascular drugs, anticonvulsants, or psychoactive substances; 6. Pregnant or lactating women and those planning pregnancy within one month during the trial; 7. Severe hearing and vision impairments; 8. Subjects unwilling to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV value; | — |
Countries
China
Contacts
Public ContactWang Ruimin
Department of Nuclear Medicine, The First Medical Center of PLA General Hospital
Outcome results
None listed